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The relationship between plasma microparticles and disease
manifestations in patients with systemic sclerosis
Abstract
OBJECTIVE: Microparticles are small, membrane-coated vesicles that can serve as novel signaling
structures between cells. The aim of the present study was to analyze the profile of microparticles in the
blood of patients with systemic sclerosis (SSc; scleroderma) and healthy controls. METHODS: The
study population consisted of 37 patients with SSc and 15 healthy subjects of comparable sex and age.
Microparticles were isolated from plasma by high-speed differential centrifugation. Microparticles were
stained with monoclonal antibodies against cell type-specific markers and were quantified by
fluorescence-activated cell sorting analyses. RESULTS: The total number of microparticles was
strongly increased in patients with SSc compared with healthy controls (mean +/- SEM 88.0 +/- 4.8 x
10(5) microparticles/ml plasma versus 42.3 +/- 9.4 x 10(5) microparticles/ml plasma; P < 0.001).
Similarly, significant increases were found for microparticles derived from platelets, endothelial cells,
monocytes, and T cells, reflecting the activation of these cells in SSc. Platelets were the most common
source of microparticles in the blood of patients with SSc (66.9 +/- 5.2% of all microparticles) and
healthy donors, followed by microparticles derived from endothelial cells (8.8 +/- 0.9% in SSc patients).
The modified Rodnan skin thickness score (MRSS) was inversely correlated with the total number of
microparticles. Furthermore, patients with cutaneous ulcers showed a significantly lower total number of
microparticles. In multivariate analysis, an additive model of age, C-reactive protein, MRSS, and
subtype of disease accounted for 55% of the variability of the total microparticle count (r = 0.744).
CONCLUSION: The number of microparticles from different cellular sources is increased in the blood
of SSc patients. Considering their role as important mediators of intercellular communication,
microparticles could be a novel link between activated cellular compartments in the pathogenesis of
SSc.
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Abstract  
 
Objective: Microparticles are small membrane-coated vesicles that can serve as 
novel signaling structures between cells. The aim of the present study was to 
analyze the profile of microparticles in the blood of patients with systemic sclerosis 
(SSc) and healthy controls. 
Methods: The study population consisted of 37 patients with SSc and 15 healthy 
subjects of comparable sex and age. Microparticles were isolated from plasma by 
high speed differential centrifugation. Microparticles were stained with monoclonal 
antibodies against cell type specific markers and quantified by FACS analyses.  
Results: The total number of microparticles per ml plasma was strongly increased in 
patients with SSc compared to healthy controls (88.0 ± 4.8 x 105 microparticles 
versus 42.3 ± 9.4 x 105; p < 0.001). Similarly, significant increases were found for 
microparticles derived from platelets, endothelial cells, monocytes and T cells, 
reflecting the activation of these cells in SSc. Platelets were the most common 
source of microparticles in the blood of patients with systemic sclerosis and healthy 
donors (SSc: 66.9 ± 5.2% of all microparticles), followed by microparticles derived 
from endothelial cells (SSc: 8.8 ± 0.9%). The modified Rodnan skin score was 
inversely correlated with the total number of microparticles. Furthermore, patients 
with cutaneous ulcers showed significantly lower number of total microparticles. In 
multivariate analysis, an additive model of age, CRP, modified Rodnan skin score 
and discrimination of diffuse or limited SSc turned out to account for 55% of the 
variability of the total microparticle count (r = 0.744). 
Conclusion: The number of microparticles from different cellular sources is 
increased in the blood of SSc patients. Considering their role as important mediators 
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of intercellular communication, microparticles could be a novel link between 
activated cellular compartments in the pathogenesis of SSc.  
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Introduction 
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology, 
which affects the skin and various internal organs. SSc is characterized by an 
activation of immune cells, peripheral vasculopathy, the occurrence of 
autoantibodies, and tissue fibrosis. The clinical manifestations of SSc are the result of 
a complex interaction of a variety of different cell types. Endothelial cell damage with 
apoptosis resulting in the loss of capillaries is considered as one of the earliest 
changes in the pathogenesis of the disease (1). There are also inadequate attempts 
to compensate for the reduced capillary density leading to the formation of tortuous, 
bushy and giant capillaries (2). Activation of the immune system with the formation of 
perivascular infiltrates is another early feature of SSc. These infiltrates are dominated 
by T cells and are thought to contribute to the activation of fibroblasts by the release 
of profibrotic cytokines such as IL-4 (3).  
Microparticles are a heterogeneous population of small, membrane-coated 
vesicles. They are released from a variety of cells during activation and apoptosis via 
an exocytic budding process. Long considered as inert debris, microparticles are now 
appreciated as important mediators of cellular crosstalk (4). Microparticles expose an 
array of antigens from their parental cells on their surface that can be used to identify 
the cell types from which they originate. Microparticles regulate inflammation, 
stimulate coagulation, affect vascular functions and have also been implicated in 
apoptosis and cell proliferation (4). Interestingly, increased numbers of microparticles 
are found in systemic inflammatory conditions such as sepsis (5) and multiple 
sclerosis (6). Recently, microparticles have also been suggested as markers of 
endothelial cell damage in vasculitis and acute coronary syndromes (5, 7). 
Since both inflammation and endothelial cell damage are hallmarks of SSc, we 
speculated that the number of microparticles might be elevated in SSc. To test this 
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hypothesis, microparticles derived from different cell types were isolated from the 
plasma of patients with diffuse and limited SSc, and the microparticle count was 
compared to that of healthy individuals. In addition, we searched for associations of 
microparticles with major clinical manifestations of SSc. Results of these studies 
indicate that levels of microparticles are elevated in the blood of patients with SSc. 
The inverse correlation with skin fibrosis suggests that microparticles may attenuate 
fibrotic disease manifestations.   
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Material and methods 
 
Patients  
Thirty-seven consecutive, unselected patients with SSc were recruited at the 
Department of Rheumatology of the University of Florence. All patients fulfilled the 
American College of Rheumatology criteria for SSc (8). There were 33 women and 4 
men with a median age of 63 years (range 29-82 years). Patients with overlap 
syndromes/mixed connective tissue disease and other connective tissue diseases 
were excluded from the study. 
Healthy volunteers (n = 15) were used as controls. The control group 
consisted of 12 women and 3 men with a median age of 55 years (range 42–70 
years). All patients and controls were of Caucasian origin. All patients signed a 
consent form approved by the ethical committee.  
 
Clinical assessment 
An extensive clinical profile was established for each SSc patient. Patients' 
characteristics are summarized in Table 1. SSc patients were classified as limited or 
diffuse SSc according to the criteria proposed by LeRoy et al. (9). The presence of 
fingertip ulcers at the time of blood drawing, other skin ulcers (“cutaneous ulcers”, 
e.g. at the lower extremities, elbows, forearms), teleangiectasias and disease 
duration since first non Raynaud symptoms were recorded. All patients reported the 
occurrence of Raynaud's phenomenon after exposure to low temperatures. The 
modified Rodnan skin score was assessed by the same experienced rheumatologist 
in all patients at 17 body areas by clinical palpation and was rated 0–3, with a 
maximum total score of 51. Disease activity was measured according to Valentini et 
al (10). 
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 Nailfold videocapillaroscopy was performed in a blinded manner for the 
analysis of microvascular abnormalities. Patients were allowed to adapt to room 
temperature (20–22°C) for at least 15 min before the examination was started. The 
nailfolds of all 10 fingers were analyzed for the following parameters: presence of 
enlarged and giant capillaries, pericapillary edema, hemorrhages, loss of capillaries, 
ramified/bushy capillaries and disorganization of the vascular distribution. According 
to these features, patients were grouped into capillaroscopy changes with an early, 
active and late pattern using the criteria proposed by Cutolo et al. (11). The early 
pattern included the criteria of few giant capillaries and capillary hemorrhages, 
relatively well preserved capillary distribution and no evident loss of capillaries. The 
criteria for the active pattern were frequent capillary hemorrhages and giant 
capillaries, moderate loss of capillaries with some avascular areas, mild 
disorganization of the capillary architecture and absent or some ramified capillaries. 
Finally, the late pattern criteria were irregular enlargement of capillaries, few or 
absent giant capillaries, absence of hemorrhages, severe loss of capillaries with large 
avascular areas, severe disorganization of the normal capillary distribution and 
frequent ramified/ bushy capillaries. It should be noted that these criteria are 
frequently used, but that some aspects of this classification are not yet validated. 
 Pulmonary involvement was examined by the carbon monoxide diffusion 
capacity using the single-breath method standardized for hemoglobin. Antinuclear 
antibodies were determined by ELISA, anti-centromere antibodies determined on 
Hep-2 cells and anti-topoisomerase I (Scl-70) antibodies were determined by 
immunoblot analysis. Plasma levels of VEGF were measured using a commercially 
available ELISA (R&D Systems, Minneapolis, USA) as described (12). Concomitant 
treatment of SSc patients included angiotensin-converting enzyme inhibitors, calcium 
channel blockers, proton-pump inhibitors, clebopride and topical glyceryl trinitrate. All 
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patients had received therapy with intravenous prostanoids (alprostadil and iloprost). 
Blood for this study was drawn after a wash-out period of at least 30 days after the 
last prostanoid infusion. None of the study patients received corticosteroids, 
methotrexate, cyclophosphamide, D-penicillamine or other potentially disease-
modifying drugs. 
 
Isolation of microparticles by differential centrifugation 
  Blood was obtained using a 19 gauge needle and collected into citrated tubes. 
Immediately after blood drawing, plasma was centrifuged at 1500 g for 10 min, 
supernatant was collected and divided into aliquots. Aliquots were stored in liquid 
nitrogen till used for the analysis.    
  The method for the isolation of microparticles by differential centrifugation has 
been established previously for various cell types (4). Four milliliters of plasma were 
centrifuged at 1500 g for 5 min to remove suspended cells. Afterwards, the cell-free 
supernatants were centrifuged at 100000 g for 20 min using a Centrikon T-1065 
centrifuge with a TST28.38 head (Kotron Instruments, Munich, Germany) and 16 x 76 
mm centrifugation tubes (Beckman instruments, Fullerton, CA, USA). The 
supernatant was removed and the pellet was washed twice with 10 ml apop buffer (5 
mM KCl, 1 mM MgCl2 and 136 mM NaCl, pH 7.4). The microparticles were then 
quantified and characterized by flow cytometry.  
 
Labeling of microparticles and flow cytometry analysis (FACS) 
 For the differentiation and quantification of microparticles derived from 
platelets, erythrocytes, granulocytes, monocytes, T cells, B cells and endothelial cells 
by FACS, microparticles were resuspended in apop buffer containing 2.5 mM CaCl2 
and 1 % microparticle-free FCS to a final volume of 500 µl as described recently (4, 
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7). Microparticles were incubated for 20 min at room temperature in the dark with 
CD42 antibodies for the detection of platelet derived microparticles, anti-human 
CD235 antibodies for erythrocytes, anti-human CD66b antibodies for neutrophils, 
anti-human CD14 antibodies for monocytes, anti-human CD3 antibodies for T cells, 
anti-human CD19 antibodies for B cells (all antibodies from Becton Dickinson, Basel, 
Switzerland) or anti-human CD144 antibodies for endothelial cells (Serotec, 
Dusseldorf, Germany), all labeled with FITC in concentrations recommended by the 
manufacturer. Unbound antibodies were removed by two washing steps at 100000 g 
for 20 min. Stainings with isotype-matched irrelevant antibodies at the same 
concentration and under the same conditions were used as controls. After the final 
washing step, microparticles were resuspended in 500 µl apop buffer, 2.5 mM CaCl2 
and 1 % microparticle-free FCS. Microparticles were counted by measuring 1 min at 
the “hi-flow” modus at the FACS Calibur flow cytometer (Becton Dickinson, 
Mansfield, MA), and the data were evaluated with CellQuest software (Becton 
Dickinson Immunocytometry System, San Jose, CA). The total number of 
microparticles was calculated by multiplication with the ratio of total volume to 
measured volume. For calculation of the number of microparticles per milliliter 
plasma the total number was divided by four. 
 
Statistical analysis 
 Statistical analysis was performed by the biostatistician of the group (DH). 
Data are expressed as mean ± standard error of the mean, if not indicated otherwise. 
Differences in microparticle counts were tested between groups composed by 
categorical parameters to assess association of these disease parameters with 
microparticle counts. Thereby, the Kruskal-Wallis test was used for analysis of more 
than two groups, and the Mann Whitney U-test for analysis of two groups. To assess 
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correlation of continuous variables with microparticle counts, Spearman’s rank 
correlation coefficients were calculated. P-values < 0.05 were considered statistically 
significant.  
Multivariate linear regression models were applied in a stepwise forward and 
stepwise backward manner to determine an optimal combination of variables 
predicting the microparticle count. Since case numbers were low relative to the 
parameters to examine, an inclusion criteria of p ≤ 0.1 was used in the stepwise 
forward procedure . In the stepwise backward procedure, an inclusion criteria of  p ≤ 
0.05 was applied. The model was calculated including a constant term. 
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Results 
 
Cellular origin of microparticles in the blood of SSc patients and controls 
The origin of microparticles in the peripheral blood was identified by staining of 
microparticles with cell-type specific surface markers. In the blood of patients with 
SSc and healthy donors, platelets were the most common source of microparticles. 
The percentage of CD42 positive microparticles was 66.9 ± 5.2% in patients with SSc 
and 70.2 ± 3.9% in healthy donors (see absolute numbers below). Endothelial cells 
were the second most common source of microparticles with CD144 positive 
microparticles accounting for 8.8 ± 0.9 (SSc) and 7.6 ± 1.2% (healthy donors) of the 
total microparticles in the blood. Lower percentages of less than 5% were found for 
microparticles from other cellular origin such as erythrocytes, granulocytes, 
monocytes, T cells and B cells.  
 
Increased numbers of microparticles in the blood of SSc patients  
Since platelet and endothelial cell microparticles were the most common 
source of microparticles in the blood, and since T cells and monocytes have been 
implicated in the pathogenesis of SSc, these microparticles were selected for further 
analysis. The absolute number of microparticles of total, platelet, endothelial cell, T 
cell and monocytes origin in patients with SSc and healthy controls are summarized 
in Figures 1A-1E.  
Patients with SSc showed 88.0 ± 4.8 x 105 microparticles/ml plasma. This total 
number of microparticles was strongly increased compared to the values that were 
found in the plasma of healthy controls (42.3 ± 9.4 x 105 microparticles/ml plasma; p 
< 0.001, Figure 1A). Elevated total numbers of microparticles per milliliter plasma 
were found in both patients with limited and diffuse systemic sclerosis (87.6 ± 4.5 x 
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105 and 89.2 ± 13.4 x 105 microparticles/ml plasma respectively, each p < 0.05 
compared to healthy controls, Figure 1A).  
Along with the higher total number of microparticles, the number of 
microparticles derived from platelets was significantly increased in patients with 
systemic sclerosis. There were 58.8 ± 4.0 x 105 CD42 positive microparticles/ml 
detectable in the plasma of SSc patients as compared to 30.4 ± 5.2 x 105 in healthy 
controls (Figure 1B). No differences in the number of platelet derived microparticles 
were found between patients with limited and diffuse SSc (59.0 ± 4.2 x 105 and 58.6 ± 
9.7 x 105 respectively, each p < 0.001 compared to controls).  
Similarly, the total number of microparticles derived from endothelial cells was 
increased compared to controls. The mean number of CD144 positive microparticles 
was 7.6 ± 0.6 x 105 for all patients with SSc, 8.2 ± 1.8 x 105 for patients with diffuse 
SSc, 7.3 ± 0.6 x 105 for patients with limited SSc and 3.0 ± 0.6 x 105 for healthy 
controls (Figure 1C). The differences between the subgroups of SSc patients were 
statistically significant compared to healthy controls (p < 0.001 for all SSc patients, p 
< 0.001 for diffuse SSc patients and p < 0.002 for limited SSc patients).  
Along with increased microparticles from endothelial cell and platelet origin, 
the number of microparticles derived from T cells and monocytes was significantly 
elevated, reflecting the activation of these cells in SSc. The mean number of CD3 
positive and CD14 positive microparticles was 4.1 ± 0.4 x 105 and 3.1 ± 0.3 x 105 
respectively compared to 1.9 ± 0.3 x 105 (p < 0.02) and 1.4 ± 0.2 x 105 (p < 0.001) in 
healthy controls (Figures 1D and 1E). The number of T cell and monocytes-derived 
microparticles was significantly elevated in both patients with limited and diffuse SSc 
without differences between these subgroups.  
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Notably, there was no difference in the platelet, erythrocyte, monocytes and T 
cell counts between SSc patients and controls, indicating that the increased number 
of microparticles was not simply caused by increased cell numbers.  
 
Concomitant diseases do not contribute to the increased number of 
microparticles in SSc patients 
Since vascular diseases such as coronary artery disease and thrombotic 
diseases such as the antiphospholipid antibody syndrome are associated with 
increased numbers of microparticles (13, 14), we next searched for confounding 
clinical parameters that could have influenced the results. Arterial hypertension was 
found in 4/37 patients with SSc (11%), and in none of the controls. All other 
established risk factors for atherosclerosis such as smoking, diabetes, 
hypercholesterolemia and hyperlipidemia were equally distributed between patients 
and controls (Table 1).  
In addition, all patients with known coronary heart disease and clinical 
manifestations of atherosclerosis such as stroke or peripheral obliterative arterial 
disease were excluded from our study.  
Similarly, there was no evidence for thrombotic diseases in the past medical 
history of patients and controls. Increased levels of antiphospholipid-antibodies were 
not detectable in patients and controls (Table 1). 
  Moreover, patients and controls with systemic infections, which are also 
associated with increased numbers of microparticles, were not included in the study. 
Taken together, these data indicate that the increased numbers of microparticles 
were not caused by confounding vascular, infectious or thrombotic diseases in our 
patient population.  
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 Correlation of microparticles with clinical manifestations of SSc  
The increased number of microparticles from endothelial cells, inflammatory 
cells and platelets likely reflects their cellular activation in the pathogenesis of SSc 
(4). Based on these findings, we hypothesized that the number of microparticles 
could be associated with clinical vascular and fibrotic manifestations of the disease.  
In fact, in univariate analysis, the number of total microparticles correlated 
significantly with the modified Rodnan Skin Score (p < 0.05, r = -0.333). As shown in 
Figure 2A, patients with a modified Rodnan Skin Score of ≥ 10 had significantly lower 
numbers of microparticles than patients with a Skin Score of < 10 (75.9 ± 7.4 x 105 
versus 97.3 ± 5.6 x 105, p < 0.05). This association was further confirmed by the 
analysis of microparticles derived from platelets. Similar to the total number of 
microparticles, the number of CD42 positive microparticles correlated significantly 
with the modified Rodnan Skin Score (p < 0.05, r = -0.337), and patients with a 
modified Rodnan Skin Score of ≥ 10 showed significantly lower levels of platelet 
microparticles than patients with a Skin Score of < 10 (51.2 ± 5.9 x 105 versus 65.3 ± 
5.2 x 105, p < 0.05, Figure 2B). There was no correlation detectable between the 
modified Rodnan Skin Score and the number of microparticles from other cell types.  
There was also an association between the total number of microparticles in the 
blood of SSc patients and the presence of cutaneous ulcers (Figure 2C). Patients 
with cutaneous ulcers (80.1 ± 4.9 x 105) had lower numbers of microparticles than 
patients without cutaneous ulcers (106.8 ± 9.1 x 105, p < 0.05). This was again 
accompanied by the same pattern in the number of platelet-derived microparticles 
(cutaneous ulcers: 52.4 ± 3.8 x 105, without cutaneous ulcers: 74.9 ± 8.7 x 105, p < 
0.05). No significant association of the total number of microparticles were observed 
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by univariate analysis with any other clinical parameter. Older patients tended to 
have lower number of microparticles, but this difference was not statistically 
significant (age > 60 years: 83.6 ± 5.8 x 105, age ≤ 60 years: 93.8 ± 7.9 x 105, p > 
0.05). There was only one patient with elevated CRP values. This patient had the 
highest number of total microparticles of all patients and an increased disease activity 
score of 3.5.  
Although many univariate analyses did not show associations of disease 
parameters with microparticle counts, a combination of them might still predict the 
increased levels in SSc patients. We checked a multivariate linear regression model 
on the total number of microparticles for age, sex, subtype of SSc, disease activity, 
CRP, duration of disease, number of platelets, modified Rodnan skin score, levels of 
VEGF, changes observed by nailfold capillaroscopy, presence of cutaneous ulcers,  
lung fibrosis, elevated sPAP, fingertip ulcers, teleangiectasias and Raynaud’s 
phenomenon. Platelet numbers were missing for four patients. For the 33 patients 
with valid numbers, neither the forward nor the backward regression process 
selected platelets into the model. Hence we recalculated the models for all 37 SSc 
patients omitting platelets from the variable list. The forward selection method led to a 
model (constant = 197.071) consisting of age (b = -0.683), modified Rodnan skin 
score (b = -2.571), limited type of SSc (b = -35.309), CRP (b = 2.538) and presence 
of cutaneous ulcers (b = -12.739), with a correlation coefficient of r = 0.764. The 
backward selection method led to a model (constant = 187.279) consisting of age (b 
= -0.599), modified Rodnan skin score (b = -2.826), limited type of SSc (b = -37.390) 
and CRP (b = 2.905), with a correlation coefficient of r = 0.744. Thus, both selection 
procedures resulted in the same variables except for the presence of cutaneous 
ulcers. Since this parameter did not show significant influence (p = 0.139) in the final 
model of the forward selection procedure, we focused on the four parameters 
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selected from both models. The respective correlation coefficient of r = 0,744 of this 
model results in a coefficient of determination R2 of 0.55. Taken together, these 
results show that as much as 55% of the variability of the total number of 
microparticles can be explained by a combination of the four parameters modified 
Rodnan skin score, limited subtype of SSc, CRP and age. 
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Discussion  
 
Microparticles represent a novel element in the communication between cells 
in biology and disease (15). Interactions between membrane molecules usually 
require direct cell-cell contact, and long-distance interactions between cells are 
mediated by soluble mediators such as cytokines. Microparticles are released from 
cellular plasma membranes and circulate as small membrane-coated vesicles in the 
peripheral blood. Thus, microparticles can mediate the communication between cells 
in that they allow membrane interactions between cells at long distances (15). The 
present study is the first report that the levels of microparticles are elevated in the 
blood of patients with SSc, suggesting that this novel mechanism of intercellular 
interaction can contribute to disease pathogenesis. 
Increased levels of microparticles have been detected in diseases with 
vascular damage such as atherosclerosis and coronary artery disease (7, 14, 16-18). 
To avoid confounding effects related to differences in the prevalence of these 
diseases, all patients with clinical evidence of coronary artery disease were excluded 
from the study. In addition, established risk factors for atherosclerosis such as 
smoking, diabetes, hypercholesterolemia and hyperlipidemia were not present in both 
SSc patients and controls (except one SSc patient with diabetes). Patients suffering 
from other diseases known to increase the numbers of microparticles in the blood 
such as infectious diseases (5, 19), vasculitis and antiphospholipid syndrome (7, 13) 
were excluded from the study. Thus, the increased number of microparticles in the 
blood of SSc patients is not a secondary phenomenon due to comorbidities, but 
rather reflects the disease process in SSc itself.  
In this regard, the release of microparticles from their parental cells is known to 
be enhanced in activated cells, e.g. by stimulation with cytokines (4). In fact, 
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increased levels of different cytokines are a main feature of the pathogenesis of SSc 
and circulating cells such as platelets, monocytes and T cells as well as endothelial 
cells are activated in SSc as indicated, for instance, by the expression of activation 
markers (20). Thus, the enhanced levels of microparticles found in SSc patients in 
our study are likely caused by an increased release of microparticles from their 
(cytokine)-activated parental cells. 
 We observed a significant inverse correlation of the total number of 
microparticles and of the number of microparticles derived from platelets with the 
modified Rodnan Skin Score. These results from the univariate analysis were further 
confirmed by the multivariate analysis, in which the modified Rodnan skin score and 
the limited subtype of SSc together CRP and age accounted for as much as 55% of 
the variability of microparticles counts. These results show that the increase in 
microparticle counts in SSc patients observed in this study is largely driven by SSc 
associated features (and age). The Rodnan skin score is the most commonly used 
and best validated outcome measure for skin fibrosis in SSc. Thus, high numbers of 
microparticles are associated with milder dermal fibrosis in SSc. Consistent with this 
finding, we previously demonstrated that microparticles potently induce the 
expression of matrix metalloproteinase (MMP)-1, MMP-3, MMP-9 and MMP-13 in a 
dose-dependent manner. In contrast, no counter-regulatory induction of the 
expression of tissue inhibitors of MMPs (TIMPs) was observed (4). Microparticles 
might, therefore, exert direct anti-fibrotic effects on fibroblasts by promoting the 
degradation of extracellular matrix. However, it has to be emphasized that functional 
experiments with SSc-derived microparticles were not part of the present study. 
Thus, the functional role of microparticles in the pathogenesis of SSc needs to be 
addressed in additional studies using SSc specific biomaterial. In addition, the results 
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of the present study are limited by the rather low number of patients that were 
examined.  
In summary, in the present study, we have demonstrated that microparticles 
derived from different cell types are significantly elevated in SSc patients. The 
number of microparticles correlated inversely with the modified Rodnan skin score. 
Thus, microparticles may contribute to the pathogenesis of SSc as a novel 
intercellular communication pathway that may attenuate certain disease 
manifestations.   
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Table 1: Patient characteristics 
 SSc-patients controls 
numbers 37 15 
Male- female-ratio 4/33 3/12 
Disease subsets 
• limited 
• diffuse 
 
27/37 
10/37 
 
--- 
--- 
mean age (years) 63 ± 12 (range 29-82 ) 56 ± 14 (range 42-70) 
diabetes 1/37 0/15 
smoking 0/37 0/15 
arterial hypertension 4/37 0/15 
hypercholesterolemia 0/37 0/15 
hyperlipidemia 0/37 0/15 
disease duration (years) 13 ± 10 (range 3-44) --- 
Pulmonary involvement 
• HRCT 
• FVC 
• DLCO 
 
18/37 
98.5 ± 20.7 % 
66.0 ± 23.0 % 
 
--- 
--- 
--- 
• Elevated sPAP by 
ECHO 
 
10/37 
 
0/15 
DMARDs 0/37 0/15 
Modified Rodnan skin score 13.6 ± 11.5 --- 
Disease activity 1.58 ± 1.40 (range 0-5.5) --- 
Finger tip ulcers 22/37 0/15 
Cutaneous ulcers 26/37 0/15 
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Levels of VEGF (pg/ml) 203 ± 87 (range 96-501) --- 
Autoantibodies 
• ANAs 
• Scl 70 
• ACAs 
 
33/37 
13/37 
16/37 
 
0/15 
0/15 
0/15 
 
ANAs: anti-nuclear antibodies, ACAs: anti-centromere antibodies, Scl-70: Scl-70 
autoantibodies, HRCT: high resolution CT, DLCO: diffusion capacity for carbon 
monoxide, FVC: forced vital capacity. Smoking: Never smokers based on past 
medical history. Arterial hypertension: Defined according to WHO criteria ≥ class I. 
Hypercholesterolemia: Total cholesterol measured with standard methods above 
normal limits (normal < 220 mg/dl). Hyperlipidemia: Fasting triglycerides measured 
with standard methods above normal limits (normal < 170 mg/dl). HRCT: normal was 
defined as no evidence for fibrosis or alveolitis as judged by an experienced 
radiologist. Elevated sPAP by ECHO: estimated systolic pulmonary artery pressure 
(sPAP) > 35 mmHg by echocardiogram performed by the same experienced 
cardiologist in all patients. Data are shown as mean ± standard deviation.  
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Figure legends 
 
Figure 1: Significant increase in the total microparticle count in patients with limited 
and diffuse SSc compared to healthy individuals (p < 0.05, Figure 1A). Similarly, the 
number of microparticles derived from platelets (p < 0.05, Figure 1B), endothelial 
cells (p < 0.05, Figure 1C), monocytes (p < 0.05, Figure 1D), and T cells (p < 0.05, 
Figure 1E) was significantly elevated in patients with limited and diffuse SSc 
compared to healthy individuals. Black rhombi represent single individuals, mean 
values are indicated by red bars. 
 
Figure 2: Association of microparticles with clinical manifestations of SSc. The total 
number of microparticles (Figure 2A) as well as the number of platelet (CD42 
positive) microparticles (Figure 2B) was significantly higher in patients with a 
modified Rodnan skin score of <10/51 compared to patients with a modified Rodnan 
skin score of ≥10/51. In addition, the total number of  microparticles were significantly 
lower in patients with cutaneous ulcers (e.g. at the lower extremities, elbows, 
forearms, Figure 2C) compared to patients without ulcers. Box plots with 25% 
percentiles and medians. # indicates significance at p < 0.05. 
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